{"product_id":"daratumumab-vs-control-treatment-for-multiple-myeloma-what-a-major-review-of-35-studies-found","title":"Daratumumab vs. Control Treatment for Multiple Myeloma: What a Major Review of 35 Studies Found","description":"\u003cp\u003eThis systematic review and meta-analysis pooled data from 35 studies and 22,439 patients to evaluate how well daratumumab works against multiple myeloma compared with control treatments. Daratumumab significantly improved overall response rates (odds ratio 2.58, 95% CI 2.26–2.93, p\u0026lt;0.01) and minimal residual disease negativity across all patient subgroups. The risk of progression or death was lower in the daratumumab group (risk difference -0.14, 95% CI -0.16 to -0.12). The overall hazard ratio was 0.50 (95% CI 0.46–0.55). This means daratumumab roughly halved the risk of progression or death. Benefits were consistent in relapsed or refractory, transplant-ineligible, and transplant-eligible patients.\u003c\/p\u003e\n\n\u003ch1\u003eDaratumumab vs. Control Treatment for Multiple Myeloma: What a Major Review of 35 Studies Found\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n\u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#what-is\"\u003eWhat Is Multiple Myeloma?\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#daratumumab\"\u003eWhat Is Daratumumab and How Does It Work?\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Researchers Conducted the Study\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#included\"\u003eWhich Studies Were Included\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#quality\"\u003eStudy Quality Assessment\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#hazard\"\u003eKey Finding: Hazard Ratio for Progression or Death\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#response\"\u003eKey Finding: Overall Response Rate\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#survival\"\u003eKey Finding: Overall Survival and Mortality\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#mrd\"\u003eKey Finding: Minimal Residual Disease Negativity\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#prd\"\u003eKey Finding: Progression or Death Risk Difference\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What the Study Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations and Actionable Advice\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eA meta-analysis of 35 studies and 22,439 patients found daratumumab roughly halved the risk of progression or death compared with control treatments in multiple myeloma.\u003c\/li\u003e\n\u003cli\u003eDaratumumab more than doubled the likelihood of achieving a treatment response, with an overall response rate odds ratio of 2.58.\u003c\/li\u003e\n\u003cli\u003ePatients receiving daratumumab had lower odds of death (odds ratio 0.73) and higher rates of minimal residual disease negativity across all subgroups.\u003c\/li\u003e\n\u003cli\u003eBenefits were consistent in relapsed\/refractory, transplant-ineligible, and transplant-eligible patients, but individual treatment decisions should be personalized.\u003c\/li\u003e\n\u003cli\u003eDaratumumab requires monitoring for increased infection risk; patients should report signs of infection promptly and discuss MRD testing with their care team.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eMultiple myeloma remains an incurable disease for most patients. Even with modern treatments, many patients experience multiple relapses and eventually develop resistance to standard therapies. This reality drives the search for better treatment options.\u003c\/p\u003e\n\n\u003cp\u003eResearchers conducted this meta-analysis to evaluate how well daratumumab works compared with control treatments. A meta-analysis combines results from many separate studies into one pooled analysis. This approach gives a broader picture than any single study can provide.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers focused on three distinct patient groups:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eRelapsed or refractory multiple myeloma (RRMM)\u003c\/strong\u003e: patients whose cancer has returned or stopped responding to prior treatments\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNewly diagnosed, transplant-ineligible (ND\/ISCT)\u003c\/strong\u003e: patients newly diagnosed who cannot receive a stem cell transplant\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNewly diagnosed, transplant-eligible (ND\/ESCT)\u003c\/strong\u003e: patients newly diagnosed who can receive a stem cell transplant\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe study authors noted that several prior meta-analyses had assessed daratumumab's efficacy. However, none had simultaneously measured its effects on minimal residual disease negativity and overall response rate. The authors also pointed out that the annual literature on daratumumab is expanding rapidly, now exceeding 30 studies per year. This growth can influence pooled estimates over time. By integrating both randomized and observational data, this meta-analysis aimed to provide the most comprehensive synthesis of daratumumab's benefits in multiple myeloma to date.\u003c\/p\u003e\n\n\u003ch2 id=\"what-is\"\u003eWhat Is Multiple Myeloma?\u003c\/h2\u003e\n\n\u003cp\u003eMultiple myeloma is a cancer of plasma cells, which are a type of white blood cell found in the bone marrow. Plasma cells normally help the body fight infection by producing antibodies. In multiple myeloma, these cells become malignant and multiply abnormally.\u003c\/p\u003e\n\n\u003cp\u003eThe disease is characterized by abnormal monoclonal protein production, bone marrow infiltration, and a complex array of clinical symptoms. These symptoms include bone pain, anemia (low red blood cell counts), and renal dysfunction (kidney problems).\u003c\/p\u003e\n\n\u003cp\u003eMultiple myeloma is the second most common hematologic malignancy (blood cancer). It accounts for approximately 1% of all cancers and 10% of hematologic cancers worldwide. Despite advancements in diagnosis and treatment, the disease remains incurable. Most patients experience multiple relapses and develop resistance to standard therapies over time.\u003c\/p\u003e\n\n\u003cp\u003eCurrent therapeutic strategies focus on extending progression-free survival (PFS) and achieving deeper, longer-lasting responses to improve overall survival. Progression-free survival is the time a patient lives without the cancer getting worse.\u003c\/p\u003e\n\n\u003ch2 id=\"daratumumab\"\u003eWhat Is Daratumumab and How Does It Work?\u003c\/h2\u003e\n\n\u003cp\u003eDaratumumab is a human monoclonal antibody that targets CD38. A monoclonal antibody is a laboratory-made protein that attaches to a specific target on cells. CD38 is a glycoprotein (a protein with sugar molecules attached) that is highly expressed on myeloma cells. This makes CD38 an ideal target for therapy.\u003c\/p\u003e\n\n\u003cp\u003eWhen daratumumab binds to CD38 on myeloma cells, it induces cell death through multiple mechanisms:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAntibody-dependent cellular cytotoxicity\u003c\/strong\u003e: immune cells are directed to attack the marked cancer cells\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eComplement-dependent cytotoxicity\u003c\/strong\u003e: a cascade of immune proteins destroys the marked cells\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAntibody-dependent cellular phagocytosis\u003c\/strong\u003e: immune cells engulf and digest the marked cancer cells\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eDaratumumab also reduces the number of immunosuppressive cells in the tumor microenvironment. These include regulatory T cells and myeloid-derived suppressor cells. By reducing these cells, daratumumab enhances the body's own immune response against myeloma cells.\u003c\/p\u003e\n\n\u003cp\u003eClinical trials have shown that daratumumab, both as a standalone treatment and in combination with other agents, leads to significant improvements in survival outcomes. These effects are especially pronounced when daratumumab is added to standard-of-care regimens. Common backbone regimens include bortezomib, lenalidomide, and dexamethasone. This combination provides a potent synergistic effect that extends the duration of response.\u003c\/p\u003e\n\n\u003cp\u003eHowever, daratumumab requires careful monitoring. Patients receiving daratumumab have an increased risk of infections and other adverse effects.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Researchers Conducted the Study\u003c\/h2\u003e\n\n\u003cp\u003eThis systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The researchers did not prospectively register the study because their project timeline did not allow for the PROSPERO review process before data extraction began. However, they strictly adhered to PRISMA throughout the project.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers conducted a comprehensive literature search across several electronic databases. These included PubMed, Web of Science, and Scopus. The search included all records available up to September 2024.\u003c\/p\u003e\n\n\u003cp\u003eRelevant Medical Subject Headings (MeSH) and keywords were used. These focused on terms like \"multiple myeloma,\" \"daratumumab,\" \"anti-CD38 therapy,\" and \"immunotherapy.\" The researchers also manually reviewed reference lists of relevant articles and prior systematic reviews. This step helped identify studies that might have been missed in the database search.\u003c\/p\u003e\n\n\u003cp\u003eEligibility criteria were defined using the PICO framework:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePopulation (P)\u003c\/strong\u003e: clinical studies on human patients diagnosed with multiple myeloma\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIntervention (I)\u003c\/strong\u003e: treatment with daratumumab, either as monotherapy or in combination with other agents\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eComparison (C)\u003c\/strong\u003e: control treatments such as standard care or alternative therapies without daratumumab\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOutcomes (O)\u003c\/strong\u003e: treatment efficacy measured by overall survival, progression-free survival, death, hazard ratio, and minimal residual disease\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eStudies were excluded if they were cross-sectional, involved animal models, were case reports, or lacked sufficient clinical outcome data. Studies focusing on other cancers or conditions were also excluded. Studies without a control group, or studies that exposed both groups to daratumumab, were excluded as well.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers included Phase II–III randomized controlled trials as well as prospective and retrospective observational cohort studies. This approach captured both high-level efficacy data and real-world effectiveness data.\u003c\/p\u003e\n\n\u003cp\u003eData extraction was independently conducted by two reviewers using a standardized data collection form. Information collected included study characteristics, patient demographics, treatment details, and outcomes measured. Discrepancies between reviewers were resolved through discussion or by involving a third reviewer.\u003c\/p\u003e\n\n\u003cp\u003eAll analyses were performed in R (version 4.x) using the meta package. The researchers assessed between-study heterogeneity with the I² statistic. They interpreted 25%, 50%, and 75% as low, moderate, and high heterogeneity, respectively. All pooled effect estimates were calculated using a DerSimonian–Laird random-effects model to yield conservative confidence intervals.\u003c\/p\u003e\n\n\u003cp\u003eTime-to-event outcomes such as progression-free survival are presented as hazard ratios (HRs) with 95% confidence intervals (CIs). Dichotomous outcomes such as MRD negativity and overall response rate are reported as odds ratios (ORs) or risk differences (RDs). Statistical significance of pooled estimates and subgroup differences was evaluated by z-tests.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers conducted predefined sensitivity analyses by omitting one study at a time to assess robustness. Subgroup analyses were conducted by study design (randomized controlled trial vs. observational) and by disease status (RRMM, ND\/ISCT, ND\/ESCT). They examined publication bias via funnel plots and Egger's regression test.\u003c\/p\u003e\n\n\u003ch2 id=\"included\"\u003eWhich Studies Were Included\u003c\/h2\u003e\n\n\u003cp\u003eThe search across PubMed, Scopus, and Web of Science yielded 24,984 studies from inception until September 2024. After removing 7,177 duplicates, 17,807 studies were screened based on title. Then 449 studies were selected for abstract evaluation, which resulted in selection of 93 articles for full-text evaluation.\u003c\/p\u003e\n\n\u003cp\u003eAmong the 93 full texts evaluated, 58 had inappropriate designs. These included case reports and case series, animal studies, and studies that did not evaluate the clinical outcome of daratumumab treatment. Histological or histomorphological studies were also excluded. The final screening resulted in the inclusion of 35 studies in the systematic review and meta-analysis.\u003c\/p\u003e\n\n\u003cp\u003eThe 35 studies were published between 2015 and 2024 and enrolled a total of 22,439 patients. The breakdown by patient group was:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eRelapsed or refractory multiple myeloma (RRMM)\u003c\/strong\u003e: 21 studies with 7,604 patients\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNewly diagnosed, transplant-ineligible (ND\/ISCT)\u003c\/strong\u003e: 12 studies with 10,216 patients\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNewly diagnosed, transplant-eligible (ND\/ESCT)\u003c\/strong\u003e: 6 studies with 4,619 patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFifteen were Phase II–III randomized controlled trials comparing daratumumab (alone or with backbone regimens such as lenalidomide or bortezomib) versus placebo or standard therapy. The remainder comprised prospective (n=2) and retrospective (n=2) observational cohorts. Sample sizes per study ranged from 45 to 1,800 patients. Studies were conducted across North America, Europe, and Asia. They reported outcomes on progression-free survival, MRD negativity, overall response rate, and safety endpoints, with follow-up durations of 6–48 months.\u003c\/p\u003e\n\n\u003cp\u003eThe backbone regimens used across studies included lenalidomide, bortezomib, melphalan, dexamethasone, cyclophosphamide, thalidomide, pomalidomide, carfilzomib, and melflufen. These were combined with daratumumab in the treatment groups and used alone or with other agents in the control groups.\u003c\/p\u003e\n\n\u003ch2 id=\"quality\"\u003eStudy Quality Assessment\u003c\/h2\u003e\n\n\u003cp\u003eStudy quality was independently rated by two reviewers. They used the Cochrane Risk of Bias 2 tool for randomized trials and the Newcastle–Ottawa Scale for observational cohorts. Discrepancies were resolved by consensus, and quality scores were explored as potential moderators in meta-regression.\u003c\/p\u003e\n\n\u003cp\u003eUsing the Cochrane Risk of Bias 2 tool, the researchers found that 28 of the 31 randomized controlled trials were judged at low risk of bias across all domains. Three trials raised \"some concerns,\" primarily due to unclear allocation concealment or missing outcome data. None were rated at high risk.\u003c\/p\u003e\n\n\u003cp\u003eFor the 4 observational cohorts assessed with the Newcastle–Ottawa Scale, total scores ranged from 6 to 9 out of 9, with a median score of 8. Three studies were deemed high quality (NOS ≥ 7), and 1 was of moderate quality (NOS=6). Most commonly, points were lost in the comparability domain due to limited adjustment for confounders.\u003c\/p\u003e\n\n\u003cp\u003eThese assessments indicate an overall low-to-moderate risk of bias in the pooled data. This supports the robustness of the meta-analytic findings.\u003c\/p\u003e\n\n\u003ch2 id=\"hazard\"\u003eKey Finding: Hazard Ratio for Progression or Death\u003c\/h2\u003e\n\n\u003cp\u003eThe overall pooled hazard ratio for daratumumab versus control treatment across all patients was 0.50 (95% CI: 0.46–0.55). This indicates a statistically significant reduction in hazard (P\u0026lt;0.01). In plain language, daratumumab roughly halved the risk of progression or death compared with control treatments.\u003c\/p\u003e\n\n\u003cp\u003eSubgroup analysis showed the following results:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eRRMM\u003c\/strong\u003e: hazard ratio of 0.48 (95% CI: 0.41–0.57) with high heterogeneity (I²=77%, P\u0026lt;0.01)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eND\/ISCT\u003c\/strong\u003e: hazard ratio of 0.52 (95% CI: 0.46–0.59) with moderate heterogeneity (I²=42%, P=0.06)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eND\/ESCT\u003c\/strong\u003e: hazard ratio of 0.55 (95% CI: 0.42–0.62) with low heterogeneity (I²=31%, P=0.21)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe overall heterogeneity was considerable (I²=67%, τ²=0.0521, P\u0026lt;0.01). However, the test for subgroup differences was not statistically significant (χ² (df=2)=0.58, P=0.75). This indicates consistent treatment effects across the subgroups.\u003c\/p\u003e\n\n\u003ch2 id=\"response\"\u003eKey Finding: Overall Response Rate\u003c\/h2\u003e\n\n\u003cp\u003eThe random-effects model analyzed a total of 4,923 patients in the daratumumab group and 4,956 patients in the control group across the three subgroups. The pooled odds ratio for overall response rate with daratumumab versus control was 2.58 (95% CI: 2.26–2.93). This shows a significant benefit in favor of daratumumab (P\u0026lt;0.01).\u003c\/p\u003e\n\n\u003cp\u003eSubgroup analyses revealed the following:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eRRMM\u003c\/strong\u003e: odds ratio of 2.43 (95% CI: 1.81–3.26) with high heterogeneity (I²=78%, P\u0026lt;0.01)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eND\/ISCT\u003c\/strong\u003e: odds ratio of 2.00 (95% CI: 1.35–2.63) with no significant heterogeneity (I²=0%, P=0.46)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eND\/ESCT\u003c\/strong\u003e: odds ratio of 2.76 (95% CI: 1.37–5.56) with moderate heterogeneity (I²=39%, P=0.18)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOverall heterogeneity was substantial (I²=70%, τ²=0.3522, P\u0026lt;0.01). Subgroup differences were statistically significant (χ² (df=2) = 6.50, P=0.04). This suggests variability in treatment effects among the subgroups.\u003c\/p\u003e\n\n\u003ch2 id=\"survival\"\u003eKey Finding: Overall Survival and Mortality\u003c\/h2\u003e\n\n\u003cp\u003eThe pooled number of patients was 5,364 in the daratumumab group and 4,870 in the control group. Across all participants, the odds of mortality were lower with daratumumab. The pooled odds ratio was 0.73 (95% CI: 0.66–0.81, P\u0026lt;0.01).\u003c\/p\u003e\n\n\u003cp\u003eAmong the subgroups, the results were:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eRRMM\u003c\/strong\u003e: odds ratio of 0.75 (95% CI: 0.66–0.85) with moderate heterogeneity (I²=45%, P=0.03)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eND\/ISCT\u003c\/strong\u003e: odds ratio of 0.76 (95% CI: 0.45–0.72) with moderate heterogeneity (I²=44%, P=0.13)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eND\/ESCT\u003c\/strong\u003e: odds ratio of 0.67 (95% CI: 0.46–0.88) with low heterogeneity (I²=12%, P=0.33)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe ND\/ESCT patients exhibited the most homogeneous results. While overall heterogeneity was present (I²=45%, τ²=0.0208, P=0.01), differences across subgroups were not statistically significant (χ² (df=2)=5.24, P=0.07).\u003c\/p\u003e\n\n\u003ch2 id=\"mrd\"\u003eKey Finding: Minimal Residual Disease Negativity\u003c\/h2\u003e\n\n\u003cp\u003eMinimal residual disease (MRD) negativity means that after treatment, no cancer cells can be detected in the bone marrow using highly sensitive tests. MRD negativity is increasingly recognized as a surrogate marker for long-term outcomes. A surrogate marker is a measurable indicator that predicts a clinical benefit.\u003c\/p\u003e\n\n\u003cp\u003eThe random-effects model included 4,097 patients receiving daratumumab and 3,528 in the control group. Daratumumab significantly improved MRD negativity rates across all subgroups.\u003c\/p\u003e\n\n\u003cp\u003eIn the detailed data, the MRD negativity events were:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eDaratumumab group: 1,489 events out of 4,123 patients assessed\u003c\/li\u003e\n\u003cli\u003eControl group: 604 events out of 3,528 patients assessed\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis means that patients receiving daratumumab were substantially more likely to achieve MRD negativity compared with those receiving control treatments.\u003c\/p\u003e\n\n\u003ch2 id=\"prd\"\u003eKey Finding: Progression or Death Risk Difference\u003c\/h2\u003e\n\n\u003cp\u003eThe risk difference for progression or death was lower in the daratumumab group. The overall risk difference was -0.14 (95% CI: -0.16 to -0.12). A negative risk difference means fewer events occurred in the daratumumab group.\u003c\/p\u003e\n\n\u003cp\u003eSubgroup analysis showed varying effects:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eND\/ESCT\u003c\/strong\u003e: risk difference of -0.11 (95% CI: -0.17 to -0.04) with moderate heterogeneity (I²=46%, P=0.16)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eND\/ISCT\u003c\/strong\u003e: risk difference of -0.10 (95% CI: -0.15 to -0.06) with similar heterogeneity (I²=54%, P=0.09)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRRMM\u003c\/strong\u003e: risk difference of -0.17 (95% CI: -0.21 to -0.13) with high heterogeneity (I²=87%, P\u0026lt;0.01)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOverall heterogeneity was substantial (I²=78%, τ²=0.0095, P\u0026lt;0.01). However, subgroup differences were not statistically significant (χ² (df=2) = 3.90, P=0.14).\u003c\/p\u003e\n\n\u003cp\u003eThe combined funnel plots revealed varying degrees of symmetry. This provides insight into potential publication bias and heterogeneity across the included studies.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis meta-analysis confirms that daratumumab provides significant clinical benefits across multiple patient subgroups. The findings support daratumumab as a robust therapeutic option for extending progression-free and overall survival in multiple myeloma.\u003c\/p\u003e\n\n\u003cp\u003eThe consistency of benefit across all three patient groups is particularly important. A patient may have relapsed or refractory disease. A patient may be newly diagnosed but cannot receive a stem cell transplant. A patient may be newly diagnosed and eligible for transplant. In all these groups, daratumumab appears to improve outcomes.\u003c\/p\u003e\n\n\u003cp\u003eThe overall hazard ratio of 0.50 means that daratumumab reduced the risk of progression or death by approximately half compared with control treatments. The odds ratio for overall response rate of 2.58 indicates that patients receiving daratumumab were more than twice as likely to respond to treatment.\u003c\/p\u003e\n\n\u003cp\u003eThe improvement in MRD negativity rates is especially meaningful. Achieving MRD negativity suggests that treatment has eliminated detectable cancer cells to a very deep level. This is increasingly recognized as a predictor of better long-term outcomes.\u003c\/p\u003e\n\n\u003cp\u003eThe mortality odds ratio of 0.73 indicates that patients receiving daratumumab had lower odds of death compared with those receiving control treatments.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What the Study Could Not Prove\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers identified several limitations. Some heterogeneity was observed across the included studies. Heterogeneity means that the studies differed in their results beyond what would be expected by chance alone.\u003c\/p\u003e\n\n\u003cp\u003ePotential publication bias was also observed. Publication bias occurs when studies with positive results are more likely to be published than studies with negative results. This can make a treatment appear more effective than it actually is.\u003c\/p\u003e\n\n\u003cp\u003eThe overall heterogeneity was considerable for the hazard ratio analysis (I²=67%). For the overall response rate analysis, heterogeneity was substantial (I²=70%). For the progression or death risk difference analysis, heterogeneity was also substantial (I²=78%).\u003c\/p\u003e\n\n\u003cp\u003eDespite these limitations, the researchers concluded that daratumumab remains a robust therapeutic option. The consistency of benefit across subgroups supports the reliability of the findings.\u003c\/p\u003e\n\n\u003cp\u003eThe study authors noted that they did not prospectively register the study because their project timeline did not allow for the PROSPERO review process before data extraction began. However, they strictly adhered to PRISMA guidelines throughout the project.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations and Actionable Advice\u003c\/h2\u003e\n\n\u003cp\u003eBased on this comprehensive meta-analysis, the following points are relevant for patients and their care teams:\u003c\/p\u003e\n\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eDiscuss daratumumab as a treatment option\u003c\/strong\u003e: For patients with multiple myeloma, whether newly diagnosed or relapsed\/refractory, daratumumab has demonstrated significant benefits across all major patient subgroups.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eUnderstand the benefits\u003c\/strong\u003e: Daratumumab roughly halved the risk of progression or death compared with control treatments. It also more than doubled the likelihood of achieving a treatment response.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAsk about MRD testing\u003c\/strong\u003e: Minimal residual disease negativity is an important marker of deep treatment response. Patients may wish to discuss MRD testing with their healthcare providers.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMonitor for infections\u003c\/strong\u003e: Daratumumab requires careful monitoring due to an increased risk of infections and other adverse effects. Patients should report any signs of infection to their care team promptly.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eConsider the patient's specific situation\u003c\/strong\u003e: The benefits of daratumumab were consistent across relapsed\/refractory, transplant-ineligible, and transplant-eligible patient groups. However, treatment decisions should always be individualized based on the patient's specific circumstances.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003ePatients should discuss the potential benefits and risks of daratumumab with their healthcare providers. This meta-analysis provides strong evidence supporting daratumumab's role in multiple myeloma treatment, but individual treatment decisions require consideration of each patient's unique medical situation.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is daratumumab and how does it work?\u003c\/h3\u003e\n\u003cp\u003eDaratumumab is a laboratory-made monoclonal antibody that targets CD38, a protein found in high amounts on myeloma cells. When it binds to CD38, it triggers immune mechanisms that destroy the marked cancer cells, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cellular phagocytosis. It also reduces immunosuppressive cells in the tumor microenvironment, helping the body's own immune response against myeloma.\u003c\/p\u003e\n\u003ch3\u003eWho can benefit from daratumumab?\u003c\/h3\u003e\n\u003cp\u003eIn a pooled analysis of 35 studies and 22,439 patients, daratumumab showed consistent benefits across three groups: relapsed or refractory multiple myeloma, newly diagnosed patients who cannot receive a stem cell transplant, and newly diagnosed patients who can receive a transplant. The risk of progression or death was roughly halved in all three groups compared with control treatments.\u003c\/p\u003e\n\u003ch3\u003eWhat does a hazard ratio of 0.50 mean for me?\u003c\/h3\u003e\n\u003cp\u003eA hazard ratio of 0.50 means that, in the pooled analysis, patients receiving daratumumab had about half the risk of their cancer progressing or of dying compared with those receiving control treatments. This finding was statistically significant and was seen across all patient subgroups, though individual results can vary.\u003c\/p\u003e\n\u003ch3\u003eWhat is minimal residual disease (MRD) negativity and why does it matter?\u003c\/h3\u003e\n\u003cp\u003eMRD negativity means that after treatment, no cancer cells can be detected in the bone marrow using highly sensitive tests. In this analysis, daratumumab significantly improved MRD negativity rates across all subgroups. Achieving MRD negativity is increasingly recognized as a marker that predicts better long-term outcomes, so patients may wish to discuss MRD testing with their healthcare providers.\u003c\/p\u003e\n\u003ch3\u003eWhat are the risks or side effects of daratumumab?\u003c\/h3\u003e\n\u003cp\u003eDaratumumab requires careful monitoring because patients receiving it have an increased risk of infections and other adverse effects. The article does not list specific side effects beyond this. Patients should report any signs of infection to their care team promptly and discuss potential benefits and risks with their healthcare providers.\u003c\/p\u003e\n\u003ch3\u003eHow was this review conducted and how reliable are its findings?\u003c\/h3\u003e\n\u003cp\u003eResearchers pooled data from 35 studies (15 randomized trials and 4 observational cohorts) involving 22,439 patients, following PRISMA guidelines. Most randomized trials were at low risk of bias. However, considerable heterogeneity was present across studies, and potential publication bias was observed, meaning the treatment could appear more effective than it actually is.\u003c\/p\u003e\n\u003ch3\u003eDoes daratumumab improve overall survival?\u003c\/h3\u003e\n\u003cp\u003eIn the pooled analysis, the odds of death were lower with daratumumab compared with control treatments, with an odds ratio of 0.73. This means patients receiving daratumumab had about 27% lower odds of death. The benefit was seen across all three patient subgroups, though differences between subgroups were not statistically significant.\u003c\/p\u003e\n\u003ch3\u003eI have multiple myeloma and my doctor recommends daratumumab — when should I get a second opinion?\u003c\/h3\u003e\n\u003cp\u003eDaratumumab roughly halved the risk of progression or death and more than doubled the likelihood of a treatment response across relapsed or refractory, transplant-ineligible, and transplant-eligible patients. Because treatment decisions should be individualized to each patient's circumstances, a second opinion can help confirm whether daratumumab, alone or added to a backbone regimen such as lenalidomide or bortezomib, fits your situation, and can review whether MRD testing is appropriate. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Daratumumab Versus Control Treatment: A Systematic Review and Meta-analysis Study of Survival Outcomes Among Multiple Myeloma Patients : Survival Outcomes of Multiple Myeloma Treatment with Daratumumab.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Salajegheh P, Salajegheh A, Yazdi Yahyaabadi F, Yazdi F.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthor affiliations:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNeuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran\u003c\/li\u003e\n\u003cli\u003eDepartment of Pharmaceutical Sciences, Tehran University of Medical Sciences, Tehran, Iran\u003c\/li\u003e\n\u003cli\u003eDepartment of Pediatrics, Kerman University of Medical Sciences, Kerman, Iran\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e GMJ (Galen Medical Journal), 2025;14:e3958\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.31661\/gmj.v14i.3958\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCorresponding author:\u003c\/strong\u003e Farzaneh Yazdi, Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKeywords:\u003c\/strong\u003e Daratumumab; Multiple Myeloma; Progression-free Survival; Minimal Residual Disease; Treatment Outcome\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47828055326876,"sku":null,"price":0.0,"currency_code":"KRW","in_stock":true}],"url":"https:\/\/diagnosticdetectives.kr\/products\/daratumumab-vs-control-treatment-for-multiple-myeloma-what-a-major-review-of-35-studies-found","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}